dc.contributorUniv N Carolina
dc.contributorEppin Pharma Inc
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T16:19:23Z
dc.date.available2018-11-26T16:19:23Z
dc.date.created2018-11-26T16:19:23Z
dc.date.issued2016-01-01
dc.identifierPharmacology & Therapeutics. Oxford: Pergamon-elsevier Science Ltd, v. 157, p. 105-111, 2016.
dc.identifier0163-7258
dc.identifierhttp://hdl.handle.net/11449/161164
dc.identifier10.1016/j.pharmthera.2015.11.004
dc.identifierWOS:000368957100007
dc.identifierWOS000368957100007.pdf
dc.description.abstractDeveloping a non-hormonal male contraceptive requires identifying and characterizing an appropriate target and demonstrating its essential role in reproduction. Here we review the development of male contraceptive targets and the current therapeutic agents under consideration. In addition, the development of EPPIN as a target for contraception is reviewed. EPPIN is a well characterized surface protein on human spermatozoa that has an essential function in primate reproduction. EPPIN is discussed as an example of target development, testing in non-human primates, and the search for small organic compounds that mimic contraceptive antibodies; binding EPPIN and blocking sperm motility. Although many hurdles remain before the success of a non-hormonal male contraceptive, continued persistence should yield a marketable product. (C) 2015 Elsevier Inc. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationPharmacology & Therapeutics
dc.relation4,072
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectEPPIN
dc.subjectMale contraception
dc.subjectSperm
dc.subjectSemenogelin
dc.subjectReproductive pharmacology
dc.titleNon-hormonal male contraception: A review and development of an Eppin based contraceptive
dc.typeOtros


Este ítem pertenece a la siguiente institución